SCHEMBL4907346

SCHEMBL4907346

CC(Oc1nc(N)nc(N)c1-c1ccccc1)N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.41
ADORA1 P30542 6/20 0.41
DHFR P00374 2/20 0.41
HEXA P06865 1/20 0.41
HEXB P07686 1/20 0.41
ADORA3 P0DMS8 1/20 0.38
ADORA2B P29275 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NOS1 P29475 1/20 0.37
PIK3CA P42336 2/20 0.36
AKT1 P31749 1/20 0.36
MTOR P42345 1/20 0.36
PKM P14618 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MGMT P16455 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913532 0.87 DHFR (0.44) ADORA2AADORA1DHFRHEXAHEXB
SCHEMBL4907336 0.81 ADORA2A (0.43) ADORA2AADORA1ADORA3ADORA2BALOX15
SCHEMBL4907342 0.75 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL4913524 0.74 ADORA2A (0.50) ADORA2AADORA1DHFRADORA3ADORA2B
SCHEMBL4907744 0.73 DHFR (0.44) ADORA2AADORA1DHFRHEXAHEXB
SCHEMBL4913514 0.72 ADORA2A (0.41) ADORA2AADORA1DHFRHEXAHEXB
SCHEMBL14231078 0.72 ADORA2A (0.35) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL28594009 0.71 DHFR (0.56) ADORA2AADORA1DHFRHEXAHEXB
SCHEMBL13650807 0.67 NOS1 (0.60) ADORA2AADORA1HSD17B10NOS1PIK3CA
SCHEMBL4258084 0.67 LRRK2 (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349859-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2013-01-08 US disclosed
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration CCND2, KDR, FLT4 ADORA2A 560/4885ADORA1 680/4885DHFR 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.